Company Overview of TaiGen Biotechnology Co., Ltd.
TaiGen Biotechnology Co., Ltd., a pharmaceutical company, engages in the development of novel therapeutics for infectious diseases, cancer, and diabetes. It offers Nemonoxacina, a drug-resistant anti-infection drug for community acquired pneumonia, diabetic foot infection, skin infections, and nosocomial pneumonia; and stem cell mobilizer products to mobilize stem cells and progenitor cells from the bone marrow into peripheral circulation, as well as for chemosensitization treatment of leukemia patients. The company also provides hepatitis C virus protease inhibitors, anti-influenza drugs, anti-gram negative drugs, and bacteria drugs. TaiGen Biotechnology Co., Ltd. was founded in 2001 and is...
138 Shin Ming Road
Founded in 2001
Key Executives for TaiGen Biotechnology Co., Ltd.
Vice President of Corporate Operations
Senior Vice President of Research
Senior Vice President of Product Development and Marketing General Manager of Taigen Beijing
Compensation as of Fiscal Year 2014.
TaiGen Biotechnology Co., Ltd. Key Developments
TaiGen Biotechnology Co., Ltd. Presents at BIO Asia International Conference, Apr-09-2014 01:00 PM
Apr 9 14
TaiGen Biotechnology Co., Ltd. Presents at BIO Asia International Conference, Apr-09-2014 01:00 PM. Venue: Grand Hyatt, Tokyo, Tokyo, Japan.
TaiGen Biotechnology Co., Ltd. Presents at Bank of America Merrill Lynch - Taiwan, Technology & Beyond 2014, Mar-21-2014 03:15 PM
Feb 3 14
TaiGen Biotechnology Co., Ltd. Presents at Bank of America Merrill Lynch - Taiwan, Technology & Beyond 2014, Mar-21-2014 03:15 PM. Venue: Shangri-La's Far Eastern Plaza Hotel, Taipei, Taiwan.
TaiGen Biotechnology Signs Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R))
Jan 15 14
TaiGen Biotechnology Company, Limited announced that they have signed an exclusive agreement with R-Pharm to develop and commercialize nemonoxacin (Taigexyn(R)) in the Russian Federation, Turkey and other members of the Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria. Under the terms of the agreement, R-Pharm will be responsible for the development, registration and commercialization of nemonoxacin in these territories and assume all associated costs. In exchange for the exclusive rights, TaiGen will receive an upfront payment and is eligible for additional regulatory and commercial milestones as well as royalties on product sales in the future.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|